D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation

Loredano Pollegioni 1,2*, Luciano Piubelli 1,2, Gianluca Molla 1,2 and Elena Rosini 1,2

1 Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Varese, Italy, 2 The Protein Factory, Politecnico di Milano and Università degli studi dell’Insubria, Milan, Italy

pLG72 is a small, primate-specific protein of 153 amino acids. It is the product of the G72 gene, expressed in testis, spinal cord, and brain. The presence of G72 transcript and pLG72 has recurrently been called into question, however G72 mRNA and pLG72 protein levels were higher in blood and brain of patients with schizophrenia than in healthy controls. On the one hand, the SNP rs2391191 corresponding to the R30K substitution in pLG72 was genetically linked to schizophrenia, reduced thickness of the brain cortex in schizophrenia-affected individuals, and altered memory function. Various lines of evidence indicated that pLG72 is a mitochondrial protein, specifically an extrinsic protein bound on the outer membrane. Over the years, pLG72 was proposed to be involved in different functions: (a) overexpression induces mitochondria fragmentation, increasing the numbers of shorter and more mobile ones which could be delivered faster to regions of intense growth and facilitating the dendritic complexity; (b) it might induce oxidative stress by interacting with methionine-R-sulfoxide reductase B2; and (c) it binds and modulates the activity of FMN-containing oxidoreductase of the respiratory complex I. The main role of this protein, however, is related to its binding to the human flavoenzyme D-amino acid oxidase (hDAAO), i.e., the main catabolic enzyme for D-enantiomer of serine. This D-amino acid is a main endogenous coagonist of the N-methyl-D-aspartate type glutamate receptor (NMDAR) involved in main functions such as synaptic plasticity, learning, memory, and excitotoxicity. For this work, we reviewed the recent literature concerning the hDAAO-pLG72 interaction, focusing on the molecular details of the interaction, the effect of hDAAO function and stability, and the cellular effects, especially on D-serine concentration. The main effects related to the pathological R30K substitution are also reported. We have highlighted the gaps in our knowledge of this human protein as well as the relevance of clarifying the molecular details of hDAAO-pLG72 interaction in order to design molecules to modulate hDAAO activity/stability and thus NMDAR function acting at the D-serine cellular level.

Keywords: D-amino acids, D-serine, flavoprotein, protein-protein interaction, schizophrenia

INTRODUCTION

The G72 and G30 genes were first identified in 2002 on the long arm of chromosome 13 in a linkage study between schizophrenia and single nucleotide polymorphisms (SNPs) (Chumakov et al., 2002; Sacchi et al., 2016). Notably, no orthologs of G72 gene are present in rodents or other species: it represents the rare case of a primate-specific gene. The longest ORF of the gene encodes for pLG72, a protein of 153 amino acids (RefSeq NM_172370, see Figure 1).
pLG72 isoform is expressed in testis, spinal cord, caudate nucleus, and amygdala libraries (Chumakov et al., 2002). In particular, pLG72 was identified in human prefrontal cortex, in primary astrocytes (Sacchi et al., 2008), and human amygdala and caudate nucleus (Kvajo et al., 2008). In transgenic mice carrying the entire human G72 gene, the highest transcript level was apparent in the testis and in selected brain regions (Otto et al., 2009; Cheng et al., 2014). However, the presence of G72 transcript and pLG72 has recurrently been called into question (Benzel et al., 2008). Western blot analysis did not reveal pLG72 expression in primary human astrocytes, glioblastoma (U251), neuroblastoma (SKN-AS and SKN-BE), hepatocellular carcinoma (HEP2G), cervical carcinoma (HeLa), and embryonic kidney (293T) cells (Kvajo et al., 2008). Immunocytochemistry revealed pLG72 only in a small fraction (0.1%) of HeLa cells.

**FIGURE 1** | G30 and G72 genes and pLG72 protein. (A) Nucleotide sequence of the G30 gene (genebank entry code AY138548.1); the gene is transcribed on the opposite DNA strand in comparison with G72. (B) Nucleotide sequence of the G72 gene; blue circles indicate nucleotides that are different in SNPs rs2391191 (AGG → AAG resulting in the R → K substitution at position 30) and rs9558562 (AAG → GAG resulting in the K → E substitution at position 62). The reported sequence codes for K30/K62 pLG72 variant (genebank entry code NM_172370.4 with A at position 89). (C) Primary and secondary structure of pLG72; residues preceding the limited proteolysis sites are shown in orange and residues modified by BS3 cross-linking reagent are shown in pink. Cross-linked K62 residue is shown in purple (Birolo et al., 2016). The secondary structure is shown according to the final homology model (blue) and as predicted by PSSpred server (purple).

**Abbreviations**: BS3, bis(sulfosuccinimidyl)suberate; CPZ, chlorpromazine; DAAO, D-amino acid oxidase; hDAAO, human DAAO; NMDAR, N-methyl-D-aspartate type glutamate receptor; SNP, single nucleotide polymorphism; SPR, surface plasmon resonance.
Higher G72 mRNA and pLG72 levels were identified in schizophrenia-affected individuals than in healthy controls (Korostishevsky et al., 2004): a higher pLG72 level was detected in plasma and in the dorsolateral prefrontal cortex of affected individuals than in healthy controls (Korostishevsky et al., 2004; Lin et al., 2014). Interestingly, recent work identified pLG72 protein but not the corresponding mRNA in six brain regions in human postmortem samples. In our opinion, the difficult (and sometimes controversial) identification of pLG72 could result from a combination of low recognition efficiency of the commercial antibodies and very low (and strictly controlled) physiological expression levels. This latter hypothesis is also supported by the high level of methylation of CpG sites observed in the G72 gene in cerebellum (Jagannath et al., 2017a).

The SNP rs2391191 (or M15) in G72 corresponds to the Arg30Lys substitution in pLG72 (RefSeq NM_172370). This SNP has been linked with lower width of the brain cortex in schizophrenia-affected individuals (Schultz et al., 2011) and with alteration in memory function (Donohoe et al., 2007). G72 gene was also correlated with other phenotypes and psychiatric disorders, e.g., bipolar disorder and major depression.

The main role of pLG72 is related to its ability to bind the enzyme D-amino acid oxidase (DAAO, EC 1.4.3.3) (Chumakov et al., 2002), i.e., the peroxisomal flavoenzyme attributed to the catabolism of D-serine (Pollegioni and Sacchi, 2010; Sacchi et al., 2012). This D-amino acid is a primary endogenous coagonist of the N-methyl-D-aspartate type glutamate receptor (NMDAR) involved in main functions such as synaptic plasticity, learning, memory, and excitotoxicity (Bear and Malenka, 1994; Henneberger et al., 2013; Paolletti et al., 2013). A decrease in D-serine concentration has been reported in psychiatric diseases such as schizophrenia and bipolar disorder: association studies have linked DAAO and pLG72 with schizophrenia susceptibility. An increase in the level of this neuromodulator has been related to acute and chronic degenerative disorders such as amyotrophic lateral sclerosis (here, the R199W substitution in pLG72) or Alzheimer’s disease (Kvajo et al., 2008). Interestingly, recent work identified pLG72 protein but not the corresponding mRNA in six brain regions in human postmortem samples. In our opinion, the difficult (and sometimes controversial) identification of pLG72 could result from a combination of low recognition efficiency of the commercial antibodies and very low (and strictly controlled) physiological expression levels. This latter hypothesis is also supported by the high level of methylation of CpG sites observed in the G72 gene in cerebellum (Jagannath et al., 2017a).

The SNP rs2391191 (or M15) in G72 corresponds to the Arg30Lys substitution in pLG72 (RefSeq NM_172370). This SNP has been linked with lower width of the brain cortex in schizophrenia-affected individuals (Schultz et al., 2011) and with alteration in memory function (Donohoe et al., 2007). G72 gene was also correlated with other phenotypes and psychiatric disorders, e.g., bipolar disorder and major depression.

The main role of pLG72 is related to its ability to bind the enzyme D-amino acid oxidase (DAAO, EC 1.4.3.3) (Chumakov et al., 2002), i.e., the peroxisomal flavoenzyme attributed to the catabolism of D-serine (Pollegioni and Sacchi, 2010; Sacchi et al., 2012). This D-amino acid is a primary endogenous coagonist of the N-methyl-D-aspartate type glutamate receptor (NMDAR) involved in main functions such as synaptic plasticity, learning, memory, and excitotoxicity (Bear and Malenka, 1994; Henneberger et al., 2013; Paolletti et al., 2013). A decrease in D-serine concentration has been reported in psychiatric diseases such as schizophrenia and bipolar disorder: association studies have linked DAAO and pLG72 with schizophrenia susceptibility. An increase in the level of this neuromodulator has been related to acute and chronic degenerative disorders such as amyotrophic lateral sclerosis (here, the R199W substitution in pLG72) or Alzheimer’s disease (Kvajo et al., 2008). Interestingly, recent work identified pLG72 protein but not the corresponding mRNA in six brain regions in human postmortem samples. In our opinion, the difficult (and sometimes controversial) identification of pLG72 could result from a combination of low recognition efficiency of the commercial antibodies and very low (and strictly controlled) physiological expression levels. This latter hypothesis is also supported by the high level of methylation of CpG sites observed in the G72 gene in cerebellum (Jagannath et al., 2017a).
the recombinant pLG72 proteins were refolded using the anionic detergent N-lauroylsarcosine, a reducing agent and at a basic pH-value. Circular dichroism analyses showed that the refolded pLG72 acquired the tertiary structure and contained a high content of α-helices. Correctly folded pLG72 showed an absorbance maximum centered at 267 nm. The detergent affects the oligomeric state of pLG72: the protein was monodispersed at a detergent concentration ≥0.025%; under optimal conditions, all the pLG72 variants were dimeric (Molla et al., 2006a; Sacchi et al., 2017). The substitutions R30K and K62E only slightly modified the protein conformation, yielding a moderately more rigid conformation than for the previous one (Tm was 3–8°C higher than that of wild-type pLG72).

Fluorescence analyses demonstrate that pLG72 possesses a binding site for large, hydrophobic molecules. pLG72 binds aromatic compounds, i.e., the cofactors FAD, FMN, and riboflavin, the antipsychotic drug chlorpromazine (CPZ), and the nucleotides GDP/GTPyS, and the sugar β-D-galactopyranoside, see Table 1 (Chumakov et al., 2002; Sacchi et al., 2008, 2017). It was previously proposed that the activity of FMN-containing oxidoreductase of complex I in mitochondria is regulated by pLG72 binding (Otto et al., 2011): as the Kd values for FMN/FAD were similar for all pLG72 variants (Sacchi et al., 2017), we exclude that the R30K substitution favors such an interaction. Notwithstanding the ability to bind nucleotides, the pLG72 variants did not show GTPase or ATPase activity (Sacchi et al., 2017).

All pLG72 variants formed the 200-kDa complex with hDAAO with a similar affinity (Table 1). Surface plasmon resonance (SPR) analyses showed a slightly stronger interaction with hDAAO for the R30K protein (Kd = 2.2 μM) than for the other pLG72 variants (Sacchi et al., 2017).

### Table 1 | Properties of pLG72 variants (Sacchi et al., 2017).

| pLG72 variants | R30 (wild-type) | R30K | K62E |
|---------------|----------------|------|------|
| Binding Kd (μM) |                |      |      |
| FAD          | 54.2 ± 9.3     | 5.07 ± 3.5 | 84.4 ± 3.2 |
| FMN          | 68.9 ± 1.9     | 36.4 ± 3.2 | 50.5 ± 4.5 |
| OPZ          | 1.69 ± 0.09    | 1.56 ± 0.20 | 1.28 ± 0.03 |
| GDP          | 287 ± 22       | 546 ± 82  | 690 ± 55 |
| GTPyS        | 72.5 ± 14.9    | 40.0 ± 8.2 | 64.6 ± 14.8 |
| HDAAO        | 3.30 ± 1.00    | 2.15 ± 0.45 | 3.40 ± 1.07 |
| (2.7F (8.3)d) |               |      |      |
| hDAAO inhibition (%) | 53 | 15 | 8 |
| D-/(D+L)-serine (%) | 3.09 ± 1.06 | 3.52 ± 1.07 | 3.68 ± 0.97 |
| Half-life (min) | 23.9 | 13.6 | 21.0 |

* Binding was determined following changes in protein fluorescence. b Determined from SPR analysis. c Sacchi et al. (2008). d Birolo et al. (2016). e Standard deviation was calculated from curve fitting. f At 1:2 hDAAO:pLG72 ratio and 30 min of incubation. g Standard deviation arises from measurement replicates.

**SUBCELLULAR LOCALIZATION OF pLG72 (AND hDAAO)**

The subcellular localization of pLG72 was investigated using U87 glioblastoma cells transfected with plasmids encoding for tagged protein variants (Sacchi et al., 2011), demonstrating a mitochondrial localization since:

a. The signal for the expressed pLG72–ECFP protein displayed a distinctive "spaghetti like" localization around the nucleus in confocal microscopy.

b. In U87 cells stably expressing pLG72–FLAG the signal distribution closely resembled that observed for pLG72–ECFP (their expression was confirmed by Western blot analysis).

c. pLG72–ECFP and pLG72–FLAG signals largely colocalized with Mitotracker Green FM dye, a specific mitochondrial marker.

d. In U87 cells stably expressing pLG72, a specific signal for this protein was evident in the intact mitochondria following the organelle immunoprecipitation using anti-TOM22 (Translocase of the Outer Mitochondrial Membrane) antibodies.

Our evidence of mitochondrial localization for pLG72 is consistent with that reported for COS-7 transfected cells, glioma U251 and primary neurons (Benzel et al., 2008; Kvajo et al., 2008). The subcellular localization of pLG72 was not modified for the R30K variant, while a diffuse cytoplasmic distribution was observed for pLG72 variants lacking the N-terminal 25 or 35 residues (a partial mitochondrial localization was apparent in ~40% of the cells; Kvajo et al., 2008). This evidence is in agreement with the classical localization of the mitochondrial targeting sequences at the N-terminal end of the protein. Concerning the subcellular localization of hDAAO, it is known to be a peroxisomal enzyme (Moreno et al., 1999; Sacchi et al., 2008; Pollegioni and Sacchi, 2010). Using cultured human astrocytes, DAAO signal was widely distributed throughout the cytoplasm with a signal pattern resembling that of PMP70, a component of peroxisomal membranes, and a partial localization in the perinuclear region of the cell (Sacchi et al., 2008, 2011). This observation suggests that, in human astrocytes, DAAO is largely confined in the peroxisomes but also partially localized outside these organelles.

The aforementioned experimental evidence implies distinct subcellular localizations for hDAAO and pLG72: their interaction is described in the following paragraph (see subsection in "Cellular studies").

**hDAAO-pLG72 INTERACTION**

**In vitro Experiments**

In 2002, using a yeast two-hybrid system, a clone of hDAAO was isolated from a human brain cDNA library using pLG72 as bait (Chumakov et al., 2002). The specific interaction of pLG72 with hDAAO was confirmed in vitro using purified recombinant proteins (Sacchi et al., 2008) by:
a. far Western blot analysis under denaturing and native conditions, which is specific for DAAOs from mammalian sources as no signal was observed using the enzyme isolated from yeast;

b. quantitative pull-down experiments;

c. spectroscopic methods, i.e., by following the fluorescence signal of the hydrophobic probe 8-anilino-naphthalene-1-sulfonate during titration of pLG72 with hDAAO;

d. gel-permeation chromatography: a 200-kDa complex made of two pLG72 monomers and two hDAAO homodimers (2 × 18 kDa + 2 × 80 kDa) was produced when the two recombinant proteins were mixed. As a control, the elution volume of yeast DAAO was not affected by adding pLG72. The elution profile was not affected by using the apoprotein form of hDAAO or by adding 40 µM free FAD or 0.1 mM CPZ;

e. SPR analysis yielded an apparent K_d of ∼2–8 µM for the hDAAO–pLG72 complex (Sacchi et al., 2008, 2017; Caldinelli et al., 2010). The presence of 20 µM of the cofactor FAD, an identical concentration of the FAD-competitive inhibitor CPZ, 35 µM of the substrate-competitive inhibitor benzoate, or 50 mM of the physiological substrate D-serine did not affect pLG72 binding and dissociation to immobilized hDAAO (Caldinelli et al., 2010).

Concerning the role of pLG72 binding to hDAAO, at first an increase in enzymatic activity of pig DAAO (80% sequence identity to hDAAO) was reported: accordingly, pLG72 was suggested to activate the flavoenzyme (Chumakov et al., 2002). We replicated the experiment under the same conditions but using our recombinant pLG72 preparation: the interaction of pkDAAO to pLG72 was still apparent in far Western blot experiments but the activity of pkDAAO was decreased (Sacchi et al., 2008). For this reason, we postulated that the key in vitro effect of pLG72 binding to hDAAO is its inactivation (Sacchi et al., 2008). Actually, when hDAAO was mixed with increasing amounts of pLG72 (at 0.06% N-lauroyl sarcosine), we observed a time-dependent inactivation: such an effect was not due to protein precipitation or proteolysis (Sacchi et al., 2008). The kinetic parameters of hDAAO on the physiological substrate D-serine were not affected by adding pLG72 nor, similarly, was coenzyme binding (Sacchi et al., 2008; Caldinelli et al., 2010). We demonstrated that following a 30-min pre-incubation, pLG72 binding decreases the amount of the flavoenzyme form that is catalytically competent, i.e., the amount of hDAAO-bound FAD cofactor that is reduced by D-serine under anaerobic conditions. The evidence that the same result was also observed using an excess of free FAD excludes that it can be due to the depletion of FAD because of its binding to pLG72.

Limited proteolysis experiments provided additional evidence of an alteration in hDAAO native conformation by pLG72 binding: the half-time for trypsinolysis of the full-length form of hDAAO diminished from 7 to 3.5 min after adding an equimolar amount of pLG72 (Caldinelli et al., 2010). In these conditions, the rate constant for the second phase of holoenzyme degradation was increased, while the time course of proteolysis of the apoprotein form of hDAAO was not altered. (Notably, the hDAAO apoprotein is less compact than the holoenzyme; thus it is more sensitive to proteolysis). Indeed, the FAD cofactor and the substrate analog trifluoro-D-alanine halved the amount of hDAAO degraded in the first (rapid) phase of proteolysis and slowed down the second phase. In contrast, by adding 0.1 mM CPZ the hDAAO-pLG72 complex was fully sensitive to proteolysis, resembling the time course observed for the apoprotein form. Overall, pLG72 binding destabilizes the hDAAO holoenzyme, an effect which is counteracted by the cofactor or by active-site ligands (Caldinelli et al., 2010).

**Cellular Studies**

The role of pLG72 was investigated at the cellular level in U87 human glioblastoma cells transfected with pEGFP-C3 expression vectors encoding for EGFP, EGFP-hDAAO, or EGFP-pLG72 proteins. D-Serine levels were decreased in cells overexpressing hDAAO, while cotransfection with pLG72 restored D-serine levels and decreased the hDAAO activity (Sacchi et al., 2008). These results highlight the cellular function of hDAAO in D-serine catabolism and confirm the role of pLG72 as a negative effector of the flavoenzyme. For the sake of completeness, we need to mention that pLG72 overexpression reportedly failed to modify the activity of endogenous DAAO in human U251 glioma cells (Kvajo et al., 2008). In this latter experiment, DAAO activity was assayed using D-proline as substrate, a compound which is also oxidized by human D-aspartate oxidase. Indeed, DAAO activity was assayed in SH-SY5Y neuroblastoma cells and in human 1321N1 cells (which have an astrocyte-like phenotype) transfected for hDAAO or cotransfected for hDAAO and pLG72 (Jagannath et al., 2017b). This work reported an increase in hDAAO activity following cotransfection in human kidney HEK293 cells, indicating a cell-specific hDAAO-pLG72 interaction. This is an intriguing proposal that requires further investigation since the DAAO and pLG72 (mRNA and protein) levels differed significantly in the three cell lines used following the nonphysiological overexpression of the two proteins and the effect on cellular D-serine level was not assessed. Indeed, the reported expression of pLG72 in HEK293 cells conflicted with the results of Kvajo et al. (2008).

In order to clarify the interaction between hDAAO and pLG72, U87 pLG72–ECFP cells were transiently transfected with the pEYFP–hDAAO expression vector (Sacchi et al., 2011). The time course of signal localization was investigated by confocal microscopy showing that at 24 h the fluorescence signal of neosynthesized EYFP–hDAAO is spread throughout the cells and is more intense in the perinuclear region where it clearly colocalized with the fluorescence of pLG72–ECFP. At longer times, the signal for EYFP–hDAAO showed a gradual compartmentalization and at 72 h after transfection the typical punctuate distribution of hDAAO was observed (corresponding to the peroxisomal localization) and the colocalization with the signal for pLG72 was marginal. Notably, using the untagged flavoprotein (by using the pIRES–hDAAO vector) the same trend in hDAAO localization was apparent (Sacchi et al., 2011). FRET analysis on U87 pLG72–ECFP cells transiently transfected with the pEYFP–hDAAO plasmid was used to verify the inferred cellular protein–protein interaction: at 24 h upon transfection, the calculated NFRET value in different cells showed a mean
figure of 0.436 ± 0.006 supporting the interaction between the two human proteins. These values were appreciably lower at longer times. Thus, we propose that pLG72 and hDAAO could (transiently) interact on the mitochondrial surface: the cytosolic form of the flavoenzyme binds pLG72 before peroxisomes are targeted.

The D-serine level and the D-/L-serine ratio were significantly higher in U87 cells stably expressing pLG72 (5.8 vs. 4.2%) (Sacchi et al., 2011), further supporting the ability of pLG72 to inhibit hDAAO activity (Sacchi et al., 2008). The time course of D-serine concentration, as well as the D-serine concentration at 24 h, differed in U87 control vs. U87 pLG72-ECFP cells following hDAAO transient expression: the interaction of pLG72 to newly synthesized hDAAO, by affecting its catalytic activity, controls the decrease in D-serine concentration. Interestingly, we demonstrated that cytosolic hDAAO is active, having a specific activity similar to that of the peroxisomal form (Sacchi et al., 2011).

At the cellular level, pLG72 affects the half-life of hDAAO. The degradation of hDAAO and pLG72 was investigated in U87 glioblastoma cells stably expressing chimeric proteins with the enhanced yellow fluorescent protein for hDAAO or its cyan variant for pLG72 (Cappelletti et al., 2014). The tag did not alter the biochemical properties of hDAAO, the interaction between the two human proteins, or the cellular distribution of the overexpressed proteins compared to untagged ones. hDAAO is a long-lived protein (t_{1/2} > 60 h) which is degraded by different pathways. The peroxisomal hDAAO was degraded by the lysosomal/endosomal pathway, also termed pexophagy, whereas the cytosolic enzyme fraction was ubiquitinated and targeted to the proteasome. On the other hand, pLG72 is a short-lived protein (t_{1/2} ≈ 25–40 min) and is degraded by the proteasome system, although it was not ubiquitinated (as also confirmed by in vitro ubiquitination experiments). Notably, pLG72 cotransfection increased the degradation rate of hDAAO (t_{1/2} from 60 to 6 h), in this way protecting against excessive cellular D-serine depletion. We suggested that pLG72, probably by recruiting additional partners, might target the cytosolic form of hDAAO in the ubiquitin-proteasome system, triggering its degradation (Cappelletti et al., 2014). This could represent a regulation process of D-serine in the hindbrain where DAAO is mainly glial, differently from the forebrain where DAAO is mainly expressed in neurons. Concerning the latter cells, in rat models, the bassoon protein present in the presynaptic zone was reported to interact with DAAO, inhibiting the enzyme and tuning the concentration of D-serine at the synapse, thus affecting NMDAR activity (Popiolek et al., 2011).

We can conclude that the interaction of pLG72 to hDAAO on the cytosolic side of the outer mitochondrial membrane induces enzyme inactivation and speeds up its degradation (Figure 2). In this way cytosolic D-serine is preserved and the cells are protected from oxidative stress by hydrogen peroxide generated by the flavoprotein in cytosol.
**pLG72 STRUCTURE-FUNCTION RELATIONSHIPS**

Insight into the structure-function relationships of pLG72 comes from different approaches.

At first, various authors focused on the use of deletion variants, an approach that resulted in differing conclusions (Table 2). By using a yeast two-hybrid approach combined with an assay of DAAO activity, it was reported that the 123–153 and 138–153 regions of pLG72 are involved in DAAO interaction and in enhancing its activity (Chang et al., 2014). A number of C-terminally truncated fragments of pLG72 (namely, 1–20, 1–35, 1–60, 1–122, 1–137, and 95–153) were coexpressed with DAAO in AH109 yeast cells. The first five variants were designed to preserve the predicted secondary structure and the 95–153 fragment so as to contain the conserved sequence present in the three G72 isoforms. Yeast two-hybrid experiments showed that the 1–137 form does not interact with DAAO while the residues spanning the 138–153 region may interact with the flavoenzyme. Actually, pull-down experiments using the 123–153 or 138–153 fragments were 1.4- and 2.2-fold more efficient than the control, respectively, in DAAO immunoprecipitation (Chang et al., 2014). The same peptides also increased the initial rate of DAAO activity (≈1.2-fold vs. control peptides), while full-length pLG72 gave a 3.5-fold increase (Table 2).

We generated the following pLG72 variants in *E. coli* cells: 1–123 (lacking the putative disordered C-terminal portion), 1–94, 72–153 (the region recognized by the Pfam database as an interaction domain), and 1–64 (Birolo et al., 2016). Interaction analysis by SPR using hDAAO immobilized on the chip surface demonstrated that all pLG72 deletion variants interacted with the flavoenzyme with a *K*ₐ in the micromolar range: deletion of the C-terminal portion favored the flavoenzyme binding (the 1–123 variant bound to hDAAO with a higher affinity in comparison to the full-length pLG72) while the lack of the N-terminal region in the 72–153 variant slightly negatively affected the hDAAO–pLG72 interaction and the 122–153 polypeptide did bind specifically to hDAAO (Table 2). *In silico* protein-protein interaction studies indicated that specific residues belonging to loops in the 1–92 region of pLG72 might interact with hDAAO (Figure 3, see below): actually, the strongest decrease in affinity for hDAAO binding was observed for the 72–153 deleted form of pLG72 lacking the residue K62 identified by cross-linking experiments (see below). On the other hand, only the last three residues in the C-terminal part of pLG72 seem to strictly interact with hDAAO, in agreement with the moderate alterations in binding affinity determined for the variants lacking the C-terminal region. Following the deletion of the region encompassing residues 65–153, the buried solvent-accessible area of C-terminally truncated fragments of pLG72 (namely, 1–20, 1–35, 1–60, 1–122, 1–137, and 95–153) can be rationalized based on the absence of exogenous FAD in the hDAAO assay generating a large amount of the inactive apoprotein form (FAD is mandatory for the assay mixture because of the weak interaction with hDAAO apoprotein) (Molla et al., 2006b).

Deletion of the N-terminal 25 amino acids partially abolished mitochondrial targeting: only ~40% of pLG72 was still localized to mitochondria, the main signal resulted in a diffuse cytoplasmic distribution (Kvajo et al., 2008). The pLG72 variant lacking the N-terminal 35 amino acids still showed a partial mitochondrial localization, whereas the absence of 50 residues at the N-terminus prompted protein degradation. On the other hand, deletion of 33 or 43 amino acids at the C-terminal end did not abolish its mitochondrial localization but affected the expression level, probably by altering the protein stability (Kvajo et al., 2008).

Notably, we cannot exclude a conformational change in comparison with the tertiary structure of the wild-type protein in any of the experiments based on pLG72 deletion variants.

The hDAAO–pLG72 complex was investigated at low resolution by limited proteolysis using different proteases coupled to ESI/MS analyses and a large excess of pLG72 protein (Birolo et al., 2016). These experiments further confirmed that pLG72 binding induces a conformational change of hDAAO, which becomes more accessible to proteases in the complex. In detail, the peptide bonds following L189, R191, L194, E249, and L250 were the main site of proteolysis in hDAAO alone but were not recognized in the pLG72-complexed form. In the latter, the peptide bonds following Y34, Y55, F167, N180, L296, R297, and E336 were proteolytically hydrolyzed. The increased sensitivity of hDAAO to proteolysis in the complex with pLG72 (Caldinelli et al., 2010; Birolo et al., 2016) implies that the overall compactness of hDAAO is decreased by this interaction. Limited proteolysis experiments indicate that conformational changes occurred in hDAAO at the C-terminal portion, which became less flexible and exposed, and at the N-terminal portion, which was only cleavable in the presence of pLG72. A more stable protein (*T*ₘ is 7°C higher) is obtained after deleting the C-terminal end of pLG72, i.e., the region with the highest degree of disorder (Table 2). Indeed, cross-linking experiments using bis(sulfosuccinimidyl)suberate (BS²) identified one cross-link between hDAAO and pLG72, i.e., K62 of pLG72 and T182 of hDAAO.

A further approach was based on structure modeling. A preliminary attempt resulted in the production of a tentative model of pLG72 structure predicted by MODELLER 9v10 associated with abolition of its activity. The lowest inhibition of hDAAO activity was observed for the shorter N-terminal pLG72 forms (i.e., 1–64 and 1–94). Notably, the results gathered on the 122–153 pLG72 fragment differ from previous studies reporting a stronger interaction with hDAAO as compared to the full-length pLG72 (Chang et al., 2014). The discrepancy can be attributed to the experimental methods used: our result arises from gel-permeation chromatography and SPR experiments on the native protein while the previous evidence is founded on a pull-down experiment employing a biotinylated pLG72 form. The reported increase in hDAAO activity at increasing pLG72 concentrations represents a further discrepancy (Chang et al., 2014), which can be rationalized based on the absence of exogenous FAD in the hDAAO assay generating a large amount of the inactive apoprotein form (FAD is mandatory for the assay mixture because of the weak interaction with hDAAO apoprotein) (Molla et al., 2006b).
| Variant | Region | Method | \(K_{d,\text{hDAAO}}\) (\(\mu M\)) | \(T_m\) (\(^{\circ}\text{C}\)) | Residual hDAAO activity\(^a\) (%) | Comments | Properties | References |
|---------|--------|--------|-------------------------------|-----------------|-------------------------------|---------|-----------|-----------|
| Wild-type (1–153) | | RE | 2.66 | 59.2 | 16 | Mitochondrial; binds hDAAO with no change in kinetic parameters | | | Sacchi et al., 2008; Birolo et al., 2016 |
| 1–64 | | RE | 2.2 | 73.7 | 72 | Compared to the wild-type, the theoretical buried solvent accessible area following hDAAO binding is halved | | | Birolo et al., 2016 |
| 1–94 | | | 2.1 | 50.9 | 62 | | | |
| 1–123 | | | 0.4 | 66.3 | 47 | | | |
| 72–153 | | | 3.7 | 64.6 | 50 | | | |
| 122–153 | | PS | | | 110 | Unspecific binding | | |
| 26–153 | | RC | | | | Partial loss of mitochondrial localization | | Kwajo et al., 2008 |
| 36–153 | | | | | | Partial loss of mitochondrial localization | | |
| 51–153 | | | | | | | | |
| 1–110 | | | | | | Low expression yield (probably because of protein instability) | | |
| 1–120 | | | | | | | | |
| 1–20 | | Y2 | | | | No interaction with hDAAO | | Chang et al., 2014 |
| 1–35 | | | | | | | | |
| 1–60 | | | | | | | | |
| 1–122 | | | | | | | | |
| 1–137 | | | | | | | | |
| 95–153 | | | | | | | | |
| 123–153 | | | | | | | | |
| 138–153 | | | | | | | | |
| 1–71 | | MM | | | | Similar to membrane bound proteins (e.g., membrane transporters or O-GlcNAc transferase) | | Kato and Fukui, 2017 |
| 72–153 | | | | | | Similar to adaptor proteins (type I DNA methyl transferase, RH bundle subdomain of G protein-coupled receptor kinase) | | |

\(\text{RE, characterization of pure recombinant protein expressed in E. coli; RC, overproduction in COS-7 cells; Y2, yeast two-hybrid system; PS, peptide synthesis; MM, molecular modeling.}\)

\(^a\) At 1:2 hDAAO:pLG72 ratio and 30 min of incubation.

\(^b\) 3.5-fold increase in hDAAO activity with wild-type pLG72.
(Sehgal et al., 2013). Unfortunately, the reliability of this model is quite low due to the lack of suitable templates, undermining the conclusions the authors made based on subsequent computational analyses. This pLG72 model was based on Gd12 protein (PDB code 1ZCA). This protein shares an overall sequence identity of ~10% with pLG72 and, even considering only a part of the template (~30%), the sequence identity was less than 30% with an extremely high BLAST E-value (4.9). Using this preliminary pLG72 model, fragments 123–153 (consisting of loop-helix-loop conformation) and 138–153 (a hairpin loop) were extracted from the predicted structure and docked to DAAO (Chang et al., 2014). Residues R38, K163, W185, G187, A188, R191, P193–Q196, and W247–L250 in hDAAO were suggested to interact with both pLG72 peptides: these hDAAO residues belong to four loops located on the protein surface. Later on, the same authors suggested that residues within the C-terminal end of pLG72 play a crucial role in ligand binding (Sehgal et al., 2015).

Most recently, reliable homology models of pLG72 tertiary structure were independently predicted by two research groups. Our group developed a three-dimensional structure model of pLG72 (named pLG72-VA) by using homology modeling and the I-TASSER server (Figure 3A) (Birolo et al., 2016). Its reliability was evaluated considering the location of the exposed regions identified by limited proteolysis, the position of K62 (the residue involved in cross-linking with hDAAO), the α-helix content (~62%, a value in agreement with the experimental figure of 73% determined by CD analysis), and the quality level by the SAVES metaserver.

Using the pLG72-VA model, in silico molecular docking analysis identified the site and the mode of CPZ binding: the predicted dissociation constant was close to the experimental value (Table I; Sacchi et al., 2008; Caldinelli et al., 2010). Next, the hDAAO-pLG72 mode of interaction was predicted in silico by protein–protein molecular docking using the ZDOCK server, which evaluated all potential pLG72-hDAAO complexes using an energy-based scoring function. Potential complexes were filtered so that the distance between the side chain T182-OH of hDAAO and the ε-NH2 group of K62 of pLG72 was within the distance constraint for the BS3 cross-linker (12.2 vs. 11.4 Å, respectively, Figure 3C). Three alternative complexes were generated and the one showing the highest agreement with limited proteolysis results and the widest hDAAO-pLG72 surface of contact was taken into consideration. Actually, 1038 Å2 in hDAAO and 1072 Å2 in pLG72 are excluded from solvent contact in the selected hDAAO–pLG72 complex, pointing to a stable interaction (Birolo et al., 2016).

In 2017, an alternative model of the 3D structure of pLG72 was produced using a hybrid ab initio approach in which the region 1–71 and 72–153 of pLG72 were independently modeled (Kato and Fukui, 2017). Comparison of the pLG72 model by Kato and Fukui (2017) with our model (Birolo et al., 2016) reveals a general similarity in the overall molecular shape and α-helix content. In addition, the position of the key residue K62 is similar between the two models, although the orientation is different (Figures 3A,B). Interestingly, the predicted structure of the N-terminal region was similar to that of membrane-bound proteins, in agreement with the proposed location of pLG72 on the surface of membranes of mitochondria (KvaJao et al., 2008; Sacchi et al., 2011). The N-terminal domain might bind to the phosphate groups of membrane lipids. On the other hand, the C-terminal region structurally resembled adaptor proteins, in particular the helix bundle that serves as the dimer interface of modification subunit of type I DNA methyltransferase. Accordingly, these authors suggested that pLG72 serves as an adaptor protein (Kato and Fukui, 2017).

**THE R30K SUBSTITUTION**

The introduction of the conservative R30K substitution in pLG72 slightly altered the protein conformation: the main effect was a more rigid conformation (Sacchi et al., 2017). This residue was...
proposed to line the binding pocket for hydrophobic ligands (Birol et al., 2016). Concerning the hDAAO inhibition after 30 min of incubation, the R30 variant was less effective, while the K62E pLG72 resulted in the highest level of inhibition (Table 1). The latter result correlates well with the highest increase in D-/(D+L)-serine level observed in U87 cells stably overexpressing the pLG72 variants as compared to the R30 pLG72 (Table 1).

Concerning the stronger inhibition of hDAAO observed for the non-conservative K62E substitution, it can be generated by an additional charge-dipole interaction between E62 (a residue proposed to be located on the protein surface) in the pLG72 variant and T182 in hDAAO, the two interacting residues identified by cross-linking experiments (Birol et al., 2016).

As the half-life of pLG72 R30K variant is significantly lower than that of its R30 variant (half-life of 13.6 vs. 23.9 min, Table 1), a value which is not modified by the K62E substitution, it is less effective in inactivating hDAAO under physiological conditions, thus producing an excessive decrease in D-serine cellular level (Figure 2), a change that can result in neurotransmission alterations since it promotes NMDAR hypofunction and schizophrenia onset (Lisman et al., 2008).

### ADDITIONAL pLG72 INTERACTORS

Searching for a binding partner of pLG72 by a yeast two-hybrid screen, the enzyme methionine-R-sulfoxide reductase B2 (MSRB2, a mitochondrial protein) was identified (Otte et al., 2014). By using a modified version of the LUMIER method to detect protein–protein interactions in HEK-293 cells, the MSRB2-pLG72 interaction was further verified. The result did not change when using GFP or myc-tagged chimeric pLG72 proteins. In neuroblastoma N2a cells, the signals for MSRB2-GFP and pLG72-GFP showed a large colocalization in cotransfected cells, and their signal also colocalized with the one for the mitochondria-specific marker Mitotracker.

The same authors failed to confirm the interaction of pLG72 with the DAAO enzyme but, intriguingly, proposed that pLG72 was involved in the cellular oxidative stress defense system. Actually, MSRB2 catalyzes the conversion of the methionine R-sulfoxide to the reduced form of methionine: its silencing exacerbates the sensitivity toward oxidative stress, while its overexpression protects from oxidative stress (Otte et al., 2014). Changes in pLG72 expression level can increase mitochondrial oxidative stress and damage, by altering MSRB2 function. Notably, NMDAR were also identified on the inner membrane of mitochondria (Korde and Maragos, 2012): these receptors, which are insensitive to glycine as coagonist, might represent a further conduit for calcium entry in mitochondria.

Indeed, pLG72 was proposed to interact with the mitochondrial FMN-containing oxidoreductase of complex I, see above (Otte et al., 2011).

### pLG72 AND hDAAO INHIBITION

A number of research groups worldwide focused on the identification/production of hDAAO inhibitors as a way to modulate NMDAR function acting on D-serine, reviewed in Sacchi et al. (2013). As pLG72 is supposed to modulate hDAAO activity in vivo, we recently focused on designing a high-throughput screen method to identify hDAAO inhibitors sensitive to the presence of pLG72 (Terry-Lorenzo et al., 2015). Two classes of compounds sensitive to pLG72 were identified: class A compounds were more potent when pLG72 was present. It is disappointing that the structure of these molecules is unknown and the mechanism of inhibition was not investigated further. The same work identified class C hDAAO inhibitors that are less potent in the presence of pLG72. These latter compounds showed a novel mechanism of hDAAO inhibition as they acted via a mixed-inhibition mechanism of action with respect to both D-serine and FAD. These compounds showed an undetectable, very slow off-rate: the prototypical compound C interacted covalently with all five hDAAO cysteines, probably because of the large amount of hDAAO present in the apoprotein (weakly packed) form in the absence of excess FAD. We proposed that in the protein-protein complex, pLG72 partially shields the cysteines of hDAAO from class C compound access, either directly or by altering the protein conformation. This investigation also confirmed that the primary effect of pLG72 was hDAAO inhibition and highlighted the specificity of class C compounds as they did not inhibit glucose oxidase or D-aspartate oxidase (Terry-Lorenzo et al., 2015).

### CONCLUSIONS

The role of pLG72 in human brain represents a puzzling and relevant subject. Up to now, the reported investigations reached conflicting conclusions, thus leaving a number of open issues. A main goal of future investigations will be to clarify the relationships between pLG72 expression, mitochondria fragmentation and oxidative stress, also seeking for a link with the inhibitory effect of hDAAO activity. This is also strictly connected with the identification of additional binding partners and their role on pLG72 subcellular localization and half-life.

In order to fully understand the pLG72-hDAAO interaction the pLG72 three-dimensional structure needs to be resolved to give more detailed knowledge of its structure–function relationships. There is an urgent need for novel drugs to treat schizophrenia, and thus the definition of the details concerning the residues involved in the protein-protein interaction will allow us to design molecules to modulate such an interaction and thus D-serine cellular levels acting on hDAAO function. The role of epigenetic modifications on G72 and DAAO genes expression in different cell lines during development and under pathological conditions will help clarify the link with main human brain functions. Actually, genetic analyses did not reach a conclusion concerning association of the G72 gene with schizophrenia susceptibility and other psychiatric disorders (Sacchi et al., 2016). Anyway, functional magnetic resonance imaging analyses showed that the SNP resulting in R30K substitution in pLG72 was related to increase cortical thickness in schizophrenia but not in healthy controls (Schultz et al., 2011): this SNP was also proposed as a novel marker of alterations in memory performance in schizophrenia.
schizophrenia-affected individuals. On this side, the level of pLG72 protein expression in schizophrenic patients vs. healthy controls is still under debate. Similarly, an open issue is related to the detection of pLG72 (protein and mRNA) in different brain regions: the present results reached conflicting conclusions. The production of sensitive and selective anti-pLG72 antibodies is mandatory to accurately detect the human protein in brain samples (see Introduction section).

REFERENCES

Bear, M. F., and Malenka, R. C. (1994). Synaptic plasticity: LTP and LTD. Curr. Opin. Neurobiol. 4, 389–399. doi: 10.1016/0959-4388(94)90101-5

Benzel, I., Kew, J. N., Viknaraaj, R., Kelly, F., de Bellerocche, J., Hirsch, S., et al. (2008). Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry 8, 94–107. doi: 10.1186/1471-244X-8-94

Birolo, L., Sacchi, S., Smaldone, G., Molla, G., Leo, G., Caldinelli, L., et al. (2016). Regulating levels of the neuromodulator D-serine in human brain: structural insight into pLG72 and D-amino acid oxidase interaction. FEBS J. 283, 3353–3370. doi: 10.1111/febs.13809

Caldinelli, L., Molla, G., Bracci, L., Lelli, B., Pileri, S., Cappelletti, P., et al. (2010). Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Protein Sci. 19, 1500–1512. doi: 10.1002/pro.429

Cappelletti, P., Campomoni, P., Pollegioni, L., and Sacchi, S. (2014). The degradation (by distinct pathways) of human D-amino acid oxidase and its interacting partner pLG72 – two key proteins in D-serine catalysis in the brain. FEBS J. 281, 708–723. doi: 10.1111/febs.12616

Chang, S. L., Hsieh, C. H., Chen, Y. J., Wang, C. M., Shih, C. S., Huang, P. W., et al. (2014). The C-terminal region of G72 increases D-amino acid oxidase activity. Int. J. Mol. Sci. 15, 29–43. doi: 10.3390/ijms15010029

Cheng, L., Haittoni, E., Nakajima, A., Woehrle, N. S., Opal, M. D., Zhang, C., et al. (2014). Expression of the G72/G30 gene in transgenic mice induces behavioral changes. Mol. Psychiatry 19, 175–183. doi: 10.1038/mp.2012.185

Chumakov, I., Blumenfeld, M., Guerasimenco, O., Cavarce, L., Palicio, M., et al. (2002). Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 99, 13675–13680. doi: 10.1073/pnas.182412499

Donohoe, G., Morris, D. W., Robertson, I. H., McGhee, K. A., Murphy, K., Kenny, N., et al. (2007). DAOA ARG30LYS and verbal memory function in schizophrenia. Mol. Psychiatry 12, 795–796. doi: 10.1038/mp.4002026

Henneberger, C., Bard, L., King, C., Jennings, A., and Rusakov, D. A. (2013). NMDA receptor activation: two targets for two co-agonists. Neurochem. Res. 38, 1156–6112. doi: 10.1007/s11064-013-0987-2

Jagnanath, V., Brotzakis, Z. F., Parrinello, M., Walita, S., and Grünblatt, E. (2017b). Controversial effects of D-amino acid oxidase activator (DAOA/G72 on D-amino acid oxidase (DAO) activity in human neuronal, astrocyte and kidney cell lines: the N-methyl D-aspartate (NMDA) receptor hypofunction point of view. Front. Mol. Neurosci. 10:342. doi: 10.3389/fnmol.2017.00342

Jagnanath, V., Marinova, Z., Monoranu, C. M., Walita, S., and Grünblatt, E. (2017a). Expression of D-amino acid oxidase (DAO/DAOA) and D-amino acid oxidase activator (DAOA/G72) during development and aging in the human post-mortem brain. Front. Neuroanat. 11:31. doi: 10.3389/fnana.2017.00031

Kato, Y., and Fukushima, K. (2017). Structure models of G72, the product of a susceptibility gene to schizophrenia. J. Biochem. 161, 223–230. doi: 10.1093/jb/mvw064

Korde, A. S., and Maragos, W. F. (2012). Identification of an N-methyl-D-aspartate receptor in isolated nervous system mitochondria. J. Biol. Chem. 287, 35192–35200. doi: 10.1074/jbc.M111.220302

Korostishovsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., Dahary, D., et al. (2004). Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 56, 169–176. doi: 10.1016/j.biopsych.2004.04.006

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

We thank the support of Fondo di Ateneo per la Ricerca.
Sacchi, S., Cappelletti, P., Giovannardi, S., and Pollegioni, L. (2011). Evidence for the interaction of D-amino acid oxidase with pLG72 in a glial cell line. Mol. Cell. Neurosci. 48, 20–28. doi: 10.1016/j.mcn.2011.06.001
Sacchi, S., Cappelletti, P., Pirone, L., Smaldone, G., Pedone, E., and Pollegioni, L. (2017). Elucidating the role of the pLG72 R30K substitution in schizophrenia susceptibility. FEBS Lett. 591, 646–655. doi: 10.1002/1873-3468.12585
Sacchi, S., Rosini, E., Pollegioni, L., and Molla, G. (2013). D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr. Pharm. Des. 19, 2499–2511. doi: 10.2174/1381612811319140002
Schultz, C. C., Nenadic, I., Koch, K., Wagner, G., Roebel, M., Schachtzabel, C., et al. (2011). Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia. Neuropsychopharmacology 36, 1747–1753. doi: 10.1038/npp.2011.56
Sehgal, S. A., Khattak, N. A., and Mir, A. (2013). Structural, phylogenetic and docking studies of D-amino acid oxidase activator (DAOA), a candidate schizophrenia gene. Theor. Biol. Med. Model. 10:3. doi: 10.1186/1742-4682-10-3
Sehgal, S. A., Mannan, S., Kanwal, S., Naveed, I., and Mir, A. (2015). Adaptive evolution and elucidating the potential inhibitor against schizophrenia to target DAOA (G72) isoforms. Drug Des. Dev. Ther. 9, 3471–3480. doi: 10.2147/DDDT.S63946
Terry-Lorenzo, R. T., Masuda, K., Sugao, K., Fang, Q. K., Orsini, M. A., Sacchi, S., et al. (2015). High-throughput screening strategy identifies allosteric, covalent human D-amino acid oxidase inhibitor. J. Biomol. Screen. 20, 1218–1231. doi: 10.1177/1087057115600413
Wang, M., Chen, H., Zhang, J., Li, W., Xie, X., and Chang, H. (2015). Identification of pLG72-induced oxidative stress using systemic approaches. BioMed Res. Int. 2015:429253. doi: 10.1155/2015/429253

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Pollegioni, Piubelli, Molla and Rosini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.